FIGO good practice recommendations on progestogens for prevention of preterm delivery

the FIGO Working Group for Preterm Birth

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Women at high risk of preterm birth (either a previous spontaneous preterm birth and/or sonographic short cervix) with a singleton gestation should be offered daily vaginal progesterone or weekly 17-OHPC treatment to prevent preterm birth. Benefit is most significant in those with prior history of preterm birth and a short cervix. For women with a previous spontaneous preterm birth and a cervix ≥30 mm the effectiveness of progesterone is uncertain. In asymptomatic women with no prior history of previous preterm birth, no mid-trimester loss, or no short cervical length, progesterone therapy is not recommended for the prevention of preterm birth. For those with unselected multiple pregnancies, progesterone therapy is not recommended for the prevention of preterm birth. Daily vaginal progesterone or weekly 17-OHPC treatment can be used for the prevention of preterm birth. The preparation used should be decided by the woman and her clinician. There is no evidence of neurological or developmental benefit or harm in babies whose mothers use progestogens for preterm birth prevention antenatally.

Original languageEnglish (US)
Pages (from-to)16-18
Number of pages3
JournalInternational Journal of Gynecology and Obstetrics
Volume155
Issue number1
DOIs
StatePublished - Oct 2021

Keywords

  • antenatal
  • child outcome
  • preterm delivery
  • prevention
  • progesterone

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'FIGO good practice recommendations on progestogens for prevention of preterm delivery'. Together they form a unique fingerprint.

Cite this